JP2024501471A5 - - Google Patents

Info

Publication number
JP2024501471A5
JP2024501471A5 JP2023535799A JP2023535799A JP2024501471A5 JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5 JP 2023535799 A JP2023535799 A JP 2023535799A JP 2023535799 A JP2023535799 A JP 2023535799A JP 2024501471 A5 JP2024501471 A5 JP 2024501471A5
Authority
JP
Japan
Prior art keywords
compound
formula
approximately
pharmaceutical composition
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/063130 external-priority patent/WO2022132652A1/en
Publication of JP2024501471A publication Critical patent/JP2024501471A/ja
Publication of JP2024501471A5 publication Critical patent/JP2024501471A5/ja
Pending legal-status Critical Current

Links

JP2023535799A 2020-12-14 2021-12-13 エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体を用いる乳がんを治療する方法 Pending JP2024501471A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125371P 2020-12-14 2020-12-14
US63/125,371 2020-12-14
PCT/US2021/063130 WO2022132652A1 (en) 2020-12-14 2021-12-13 Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Publications (2)

Publication Number Publication Date
JP2024501471A JP2024501471A (ja) 2024-01-12
JP2024501471A5 true JP2024501471A5 (cg-RX-API-DMAC7.html) 2024-12-23

Family

ID=79288002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535799A Pending JP2024501471A (ja) 2020-12-14 2021-12-13 エストロゲン受容体分解剤としてのテトラヒドロナフタレン誘導体を用いる乳がんを治療する方法

Country Status (11)

Country Link
US (1) US20220193072A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259137A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024501471A (cg-RX-API-DMAC7.html)
KR (1) KR20230121801A (cg-RX-API-DMAC7.html)
CN (1) CN116744925A (cg-RX-API-DMAC7.html)
AU (1) AU2021401580A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202592A1 (cg-RX-API-DMAC7.html)
IL (1) IL303143A (cg-RX-API-DMAC7.html)
MX (1) MX2023007058A (cg-RX-API-DMAC7.html)
TW (1) TW202237117A (cg-RX-API-DMAC7.html)
WO (1) WO2022132652A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2021041348A1 (en) 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
CN115746058A (zh) * 2021-09-03 2023-03-07 南京知和医药科技有限公司 一种多环化合物在制备抗肿瘤药物方面的用途
EP4554948A1 (en) * 2022-07-12 2025-05-21 Regents of the University of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024049926A1 (en) * 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2024196053A1 (ko) * 2023-03-17 2024-09-26 재단법인 대구경북첨단의료산업진흥재단 에스트로겐-연관 수용체 감마 억제제 및 항암제의 병용요법용 조성물
TW202440096A (zh) * 2023-03-24 2024-10-16 美商亞文納營運公司 雌激素受體降解劑之給藥方案
JP2026518466A (ja) * 2023-06-02 2026-06-08 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解剤とakt阻害剤との組み合わせ
JP2026519559A (ja) 2023-06-02 2026-06-16 ファイザー・インク エストロゲン受容体分解薬およびcdk4阻害剤の組合せ
WO2025122502A1 (en) * 2023-12-04 2025-06-12 Foundation Medicine, Inc. Methods for treating hr-positive her2-negative breast cancer
CN121646481A (zh) * 2024-07-04 2026-03-10 海创药业股份有限公司 一种雌激素受体降解剂和akt抑制剂联合用药物及其用途
WO2026128391A1 (en) 2024-12-09 2026-06-18 Arvinas Operations, Inc. Combinations of vepdegestrant and cdk4/6 inhibitors for treating esr1-mutant breast cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG11201607334YA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
MX384605B (es) * 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
CA3095912A1 (en) * 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX2021006411A (es) * 2018-12-06 2021-07-21 Radius Pharmaceuticals Inc Metodos para el tratamiento del cancer resistente a inhibidores de cinasa 4 y cinasa 6 dependiente de ciclina (cdk4/6).
WO2021041348A1 (en) * 2019-08-26 2021-03-04 Arvinas Operations, Inc. Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

Similar Documents

Publication Publication Date Title
US12280050B2 (en) Therapeutic compositions, combinations, and methods of use
US20120157472A1 (en) Method for treating colorectal cancer
CN101677977A (zh) 用于治疗癌症的ERα+配体和组蛋白脱乙酰化酶抑制剂组合
JP2024533423A (ja) 薬学的組成物およびその使用
EP2662082A1 (en) Administration of mTOR inhibitors
WO2023081830A2 (en) Compositions and treatments with nirogacestat
US20250186446A1 (en) Organic compounds
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
WO2020233602A1 (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
TWI719765B (zh) 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療
CN118678958A (zh) 药物组合物及其用途
JP2025163103A (ja) 放射線および/または抗がん治療補助療法としてアデノシン二リン酸リボースの活用
TW201309298A (zh) 治療惡性神經膠質瘤之醫藥組合物
US20230038138A1 (en) Combination therapy for treating cancer
US20200237779A1 (en) Combination therapy with a bet inhibitor and a bcl-2 inhibitor
CN119894514A (zh) 药物组合物及其用途
HK40130794A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
HK40116696A (en) Pharmaceutical composition and use thereof
HK40110967A (en) Pharmaceutical composition and use thereof